What are the differential diagnoses for a postmenopausal woman with markedly elevated total testosterone (~112 ng/dL), low dehydroepiandrosterone (≈10 µg/dL), and virilization (hirsutism, deep voice, alopecia)?

Differential Diagnosis for Postmenopausal Hyperandrogenism with Markedly Elevated Testosterone

In a postmenopausal woman presenting with total testosterone of 112 ng/dL (~4 nmol/L), low DHEA-S of 10 µg/dL, and virilization (hirsutism, deep voice, alopecia), the primary differential diagnosis is an androgen-secreting tumor—either ovarian or adrenal—which must be ruled out urgently. 1

Critical Diagnostic Threshold

• Testosterone >150 ng/dL (>5 nmol/L) in postmenopausal women is strongly associated with virilization and mandates immediate investigation for androgen-producing tumors. 1 While this patient's level of 112 ng/dL falls slightly below this threshold, the presence of virilization (deep voice, alopecia, hirsutism) elevates clinical suspicion significantly.

• The combination of markedly elevated testosterone with low/normal DHEA-S suggests an ovarian rather than adrenal source, as adrenal tumors typically elevate DHEA-S (>600 µg/dL). 2, 3

Primary Differential Diagnoses (Ranked by Likelihood)

1. Ovarian Androgen-Secreting Tumor (Most Likely)

• Ovarian tumors account for 1-3 per 1,000 patients with hirsutism and comprise <0.5% of all ovarian tumors, but are the leading cause of severe postmenopausal virilization. 4

• Specific tumor types include:

  • Hilus cell tumors (Leydig cell tumors): produce pure testosterone with normal DHEA-S and androstenedione 5
  • Sertoli-Leydig cell tumors: can present with isolated testosterone elevation 1
  • Steroid cell tumors: may secrete testosterone preferentially 4

• Key clinical features: rapid onset of virilization (weeks to months), clitoromegaly, deep voice, male-pattern alopecia, and markedly elevated testosterone. 1, 4

2. Ovarian Hyperthecosis

• Characterized by nests of luteinized theca cells scattered throughout ovarian stroma that produce androgens, typically presenting with severe hyperandrogenism in postmenopausal women. 6

• Distinguishing features: bilateral ovarian involvement, often with normal-appearing ovaries on imaging (homogeneous, normal size), making diagnosis challenging. 6

• Laboratory pattern: markedly elevated testosterone (often >200 ng/dL), hyperinsulinemia, and metabolic syndrome features. 6

• Critical pitfall: imaging studies are frequently misleading and may appear normal despite severe biochemical hyperandrogenism. 6

3. Pure Testosterone-Secreting Adrenal Adenoma (Less Common but Important)

• Extremely rare but documented: adrenal adenomas can produce isolated testosterone elevation with normal DHEA-S, androstenedione, and cortisol. 3

• This patient's low DHEA-S (10 µg/dL) does NOT exclude adrenal origin—case reports demonstrate pure testosterone-secreting adrenal adenomas with completely normal adrenal androgens. 3

• Key teaching point: "source identification of hyperandrogenemia based solely on testosterone, DHEA-S, and androstenedione levels is limited." 3

4. Polycystic Ovary Syndrome (PCOS) in Menopause

• PCOS is the most common cause of postmenopausal hyperandrogenism overall (accounting for 70-80% of cases), but typically presents with mild-to-moderate testosterone elevation (50-80 ng/dL), not severe virilization. 7, 1

• This diagnosis is LESS likely given the severity of virilization and testosterone level, but should be considered if imaging excludes tumors. 1

5. Exogenous Androgen Exposure

• Medications or supplements containing testosterone, DHEA, or anabolic steroids can cause virilization. 2, 7

• Obtain detailed medication history including over-the-counter supplements, compounded hormones, and partner's testosterone gel exposure. 2

Immediate Diagnostic Workup

First-Line Laboratory Testing (Morning Fasting Sample)

• Repeat total testosterone by LC-MS/MS to confirm elevation (immunoassays are inaccurate at high levels). 2, 1

• Free testosterone (calculated free androgen index or equilibrium dialysis) to assess bioavailable androgen. 2, 1

• DHEA-S (already obtained: 10 µg/dL—low/normal, suggesting ovarian source). 2, 3

• Androstenedione: may be elevated in ovarian tumors but can be normal in pure testosterone-secreting tumors. 3, 1

• 17-hydroxyprogesterone (early morning) to exclude non-classic congenital adrenal hyperplasia. 7, 4

• Prolactin and TSH to exclude hyperprolactinemia and thyroid disease. 2, 7

• 24-hour urinary free cortisol or overnight dexamethasone suppression test to exclude Cushing's syndrome. 4

• Inhibin B: elevated in granulosa-theca cell tumors. 4

Imaging Studies (Perform Urgently)

• Transvaginal ultrasound as first-line imaging for ovaries, though normal appearance does NOT exclude ovarian hyperthecosis or small tumors. 1, 6

• Pelvic MRI with contrast is superior to ultrasound for detecting small ovarian masses and characterizing adnexal lesions. 1, 4

• Adrenal CT or MRI to evaluate for adrenal adenoma or carcinoma, even with normal DHEA-S. 3, 1, 4

• PET-CT may help differentiate benign from malignant lesions and exclude ectopic tumors. 3

Critical Diagnostic Algorithm

1. If imaging identifies a discrete ovarian or adrenal mass: proceed to surgical excision (bilateral salpingo-oophorectomy for ovarian tumors; adrenalectomy for adrenal tumors). 3, 1, 4

2. If imaging shows normal ovaries and adrenals but testosterone remains markedly elevated: consider ovarian hyperthecosis and proceed to bilateral salpingo-oophorectomy, as imaging is unreliable. 6

3. If testosterone normalizes after repeat testing and no mass is found: consider exogenous androgen exposure or laboratory error. 2

Treatment Approach

Surgical Management (Definitive)

• Bilateral salpingo-oophorectomy is curative for ovarian tumors and hyperthecosis, with rapid normalization of testosterone levels postoperatively. 3, 5, 6

• Total abdominal hysterectomy with bilateral salpingo-oophorectomy is recommended if endometrial hyperplasia is present (due to unopposed estrogen from chronic anovulation). 6

• Unilateral adrenalectomy for adrenal adenomas results in immediate testosterone normalization. 3

Medical Management (Temporizing or Non-Surgical Candidates)

• GnRH agonists/antagonists can suppress ovarian androgen production in women unfit for surgery or when the source is unidentified. 4

• Spironolactone 100-200 mg daily for symptomatic hirsutism, though it does not address the underlying tumor risk. 7

• Combined oral contraceptives are contraindicated in postmenopausal women and do not address tumor risk. 7

Common Pitfalls to Avoid

• Do not assume low DHEA-S excludes adrenal tumors—pure testosterone-secreting adrenal adenomas exist with completely normal adrenal androgens. 3

• Do not rely on imaging alone—ovarian hyperthecosis frequently presents with normal-appearing ovaries on ultrasound and MRI. 6

• Do not delay surgical evaluation—virilization with markedly elevated testosterone requires urgent exclusion of malignancy. 1, 4

• Do not attribute symptoms to "normal menopause"—postmenopausal women should have testosterone <50 ng/dL; levels >100 ng/dL are pathologic. 1